UCLA scientists test new strategy that could help fight ovarian cancer
UCLA scientists have developed a promising novel method to treat gynecologic tumors. The approach focuses on a protein called p53, which is commonly mutated in women who have high-grade serous ovarian cancer, the deadliest form of reproductive cancer. In many women with the disease, the cancer is very advanced by the time it is diagnosed and is therefore difficult to treat. The discovery was the result of a three-year study co-led by David Eisenberg and Dr. Sanaz Memarzadeh, members of the UCLA Jonsson Comprehensive Cancer Center. The findings, which were published online in the journal Cancer Cell, could ultimately lead to new targeted therapies for many other types of cancer carrying similar p53 mutations. P53 is known as the “guardian of the genome.” It prevents damaged cells from reproducing by stopping their growth until the damage is repaired or, if the damage cannot be reversed, promotes cell death. But mutations, which are found in 96 percent of patients with high-grade serous ovarian tumors, can cause p53 to form clumps, or “aggregates,” which impair the protein’s normal function. As a result, the damaged cells are able to multiply uncontrollably, which can lead to cancer. The UCLA scientists developed and tested a peptide called ReACp53, which penetrates cancer cells and prevents mutated p53 from clumping together. The technique restores normal p53 function, causing death of the ovarian cancer cells. “Our lab has worked for 15 yea...
Authors: Fortier E, Drobetsky E, Wurtele H PMID: 30783508 [PubMed]
Johnson&Johnson said in a regulatory filing that it had received subpoenas from the Justice Department and the Securities and Exchange Commission amid inquiries into its talc-based products.
The company said in a regulatory filing that it had received subpoenas from the Justice Department and the Securities and Exchange Commission related to its talc-based products.
SummaryOvarian cancer (OC) is the foremost lethal gynaecologic malignancy and among the top five deadliest cancers in women. Current treatment comprises a combination therapy of surgery, platinum-based chemotherapy and anti-vascular endothelial growth factor (VEGF) antibodies. However, patients typically experience a disease relapse within two years. Recurrent OC is incurable and resistance to platins and anti-VEGF treatment is a major determinant of prognosis. Understanding the molecular mechanisms that contribute to tumour metastasis and chemoresistance are essential to improve patient outcome and especia...
AbstractThe author engages in further debate between numerous signatories of a letter who disputes that the author has put forward that the anticipated benefits of a personalised program for cancer prevention and screening are unwarranted. In the event that a cancer screening program is an effective means of mortality reduction, then the best strategy is universality. The benefit of a novel intervention should be evaluated prior to its introduction.
ConclusionThe provision of genetic testing to high-risk women with a BRCA1 and two mutation probability of ≥ 10% based on the individual family cancer history appears to be a cost-effective option for the SHI.
This study provides significant and novel information regarding the frequency, causes, and consequences of elevated FOXM1 expression in human cancer.
-Fang Cheng We aimed to determine prognostic factors of early stage (I/II) epithelial ovarian carcinoma (EOC) including clinicopathologic and chemotherapeutic regimens. Four hundred and thirty-seven women who underwent primary staging surgery with adjuvant chemotherapy between January 1, 2000 and December 31, 2010 were retrospectively reviewed and analyzed from two medical centers. The prognostic factors were determined from multivariate survival analyses using Cox regression models. The majority of women were diagnosed with stage Ic (244/437, 55.8%). The histopathologic types were clear cell (37.5%), endometrioid (27....
We report a patient with Crohn’s disease who was diagnosed with signet-ring cell carcinoma in the setting of a Crohn’s flare. Diagnosis was made with endoscopy. Treatment included laparoscopic-assisted right hemicolectomy with ileostomy with subsequent chemotherapy as an outpatient .Case Rep Gastroenterol 2019;13:85 –88
Condition: Ovarian Cancer Intervention: Other: Biopsy Sponsor: Hillel Yaffe Medical Center Not yet recruiting
More News: Cancer | Cancer & Oncology | Cancer Therapy | Chemistry | Chemotherapy | Computers | Health | Laboratory Medicine | National Institutes of Health (NIH) | Neurology | Neurosurgery | OBGYN | Ovarian Cancer | Ovaries | Stem Cell Therapy | Stem Cells | Study | Universities & Medical Training | Women